Overview
- CDSCO issued a notice applying revised Schedule M requirements to every pharmaceutical unit from January 1, with strict action promised for violations.
- The order, signed by Drugs Controller General Rajeev Singh Raghuvanshi, directs immediate state inspections and elevates enforcement to top priority.
- Officials rejected further extensions that had previously given smaller manufacturers until December 2025, reversing the staggered timeline.
- Reporting links India-made cough syrups to more than 140 child deaths across Africa and Central Asia and to 24 deaths in central India.
- Products cited in coverage include Coldrif from Sresan Pharmaceutical, Respifresh TR from Rednex Pharmaceuticals, and ReLife from Shape Pharma, as industry groups warn of possible closures and higher prices.